Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Daniel P. Petrylak*, Ronald de Wit, Kim N. Chi, Alexandra Drakaki, Cora N. Sternberg, Hiroyuki Nishiyama, Daniel Castellano, Syed A. Hussain, Aude Flechon, Aristotelis Bamias, Evan Y. Yu, Michiel S. van der Heijden, Nobuaki Matsubara, Boris Alekseev, Andrea Necchi, Lajos Geczi, Yen-Chuan Ou, Hasan Senol Coskun, Wen-Pin Su, Jens BedkeGeorgios Gakis, Ivor J. Percent, Jae-Lyun Lee, Marcello Tucci, Andrey Semenov, Fredrik Laestadius, Avivit Peer, Giampaolo Tortora, Sufia Safina, Xavier Garcia del Muro, Alejo Rodriguez-Vida, Irfan Cicin, Hakan Harputluoglu, Scott T. Tagawa, Ulka Vaishampayan, Jeanny B. Aragon-Ching, Oday Hamid, Astra M. Liepa, Sameera Wijayawardana, Francesca Russo, Richard A. Walgren, Annamaria H. Zimmermann, Rebecca R. Hozak, Katherine M. Bell-McGuinn, Thomas Powles, Maureen Aarts - Essers, RANGE Study Investigators

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)105-120
Number of pages16
JournalLancet oncology
Volume21
Issue number1
DOIs
Publication statusPublished - Jan 2020

Keywords

  • ENDOTHELIAL GROWTH-FACTOR
  • BLADDER-CANCER
  • OPEN-LABEL
  • ANGIOGENESIS
  • BEVACIZUMAB
  • EXPRESSION
  • ATEZOLIZUMAB
  • CHEMOTHERAPY
  • MULTICENTER
  • VINFLUNINE

Cite this